Enhancing Lead Generation to Accelerate Quality Compounds Into Lead Optimisation

Total Page:16

File Type:pdf, Size:1020Kb

Enhancing Lead Generation to Accelerate Quality Compounds Into Lead Optimisation Pharma IQ presents Europe’s dedicated forum for fast, effective & integrated lead discovery Save up to £200 by booking early (see back page) HIT-HIT-TOTO-LEAD-LEAD Enhancing lead generation to accelerate quality compounds into lead optimisation Conference: 18th & 19th July 2005 • Masterclass: 20th July 2005 Detailed case studies will be Café Royal, London, UK presented by: Discover the hit-to-lead successes and failures experienced by Pfizer leading pharma companies to understand how you can improve Roche decision-making and generate better quality leads faster. Wyeth ➨ Explore proven and creative hit-to-lead strategies and key criteria to increase the speed and efficiency of your drug discovery processes AstraZeneca ➨ Enhance the quality of validated hits to improve the prioritisation and Bayer Healthcare selection of hit and lead series Merck KGaA ➨ Analyse DMPK data effectively to optimise properties at an early stage and to drive and prioritise hit-to-lead projects University of Sheffield ➨ Optimise ligand-based and structure-based approaches to virtual Sanofi-Aventis screening to aid lead identification and assessment ➨ Apply chemogenomics to enhance all stages of early drug discovery Tripos ➨ Improve the design and quality of hit-to-lead libraries to speed the University of generation and optimisation of lead series Heidelberg ➨ Ensure research efforts are focussed only on the most promising compounds to increase the number of successful candidates in your Novartis development pipeline Inpharmatica Don’t miss the interactive masterclass on 20th July GPC-Biotech Chemogenomics in Drug Discovery Led by Professor Hugo Kubinyi IMIM Media Partners “Excellent networking opportunities, Johnson & Johnson very interesting presentations.” Vincent Mikol, Sanofi-Aventis Array Biopharma +44 (0)20 7368 9300 +44 (0)20 7368 9301 www.iqpc-pharma.com/2484a UK Freephone: 0800 652 2363 [email protected] to-lead. It will discuss how high quality materials are provided to improve the DAY ONE: 18th July 2005 speed and quality of the process, and in particular will discuss: • Optimising hit finding and generation 08:30 Coffee and registration • Exploring the best approaches and technologies for screening • Providing excellent starting points for hit-to-lead 09:00 Pharma IQ welcome Martin Klumpp, Lab Head, Assay Development & Screening, Novartis 09:10 Opening remarks and presentation from the Chair: 15:00 Enhancing hit quality and diversity from HTS through evolving Search for new leads - from serendipity to design hit selection schemes The pharmaceutical industry is short of new drugs. As only a few lead structures The HTS process at Wyeth is currently undergoing considerable change, and the can be optimised to clinical candidates and many such projects fail in the process by which project teams select from the hits generated by HTS is clinics, there is an urgent need for new leads. This presentation will discuss and evolving to keep pace. The consistent focus has been on enhancing the quality explore the following lead sources and strategies: (in terms of 'lead-likeness') and diversity (in terms of chemical scaffolds, • Plant and microbial natural products fingerprints, etc) of the selected hits. After secondary screening and further • Serendipitous and rational approaches filtering, this approach aims to provide the team with the best possible • Chiral and metabolic switch selection of candidates for the lead optimisation phase of the project. The • Combinatorial chemistry various methods of hit selection and filtering that have been employed and the • Virtual screening evolution of the process will be presented, exemplified by results from several • Structure-based, computer-aided and fragment-based design recent and representative projects at Wyeth. Hugo Kubinyi, Professor of Pharmaceutical Chemistry, Iain McFadyen, Senior Research Scientist II, Chemistry and Screening Sciences, University of Heidelberg, and formerly BASF Wyeth 10:00 The hit-to-lead process at Bayer Healthcare 15:45 Coffee In the hit selection process, the understanding of compound liabilities needs to be ensured as early as possible in order to identify leads with the minimum 16:15 Application and benefits of knowledge-driven chemistry number of liabilities. This presentation will explore the key requirements and Tripos Discovery Research employs knowledge-driven informatics processes to features of Bayer’s hit-to-lead process, and will discuss two case studies in computationally assess every compound it makes for biological relevance and Cancer and Thrombosis. The session will consider: synthetic feasibility. These proven technologies have enabled Tripos to reduce its • In silico parameters customers' lead identification and optimisation timelines by up to 30%. Case • In vitro high throughput screening data studies will be presented that support this approach to lead identification and • Physicochemical and ADMET data the development of follow-up compound libraries. Berthold Hinzen, Director of Medicinal Chemistry, Dr. Mark Allen, Senior Vice President, Discovery Research and Managing Bayer Healthcare Director, Tripos Discovery Research, Ltd. 10:45 Coffee 17:00 Lead discovery at Roche Palo Alto This presentation will focus on the development approaches that are being 11:15 Hit identification and validation to speed hit-to-lead implemented in Roche to enhance the cross-functional process of lead High throughput screening and other hit generation techniques usually result in discovery. Multiple approaches for novel lead finding and tools to assess the huge numbers of actives being identified. Over the last couple of years, Merck hits identified will be described. Examples of the application of these tools will KGaA has implemented various processes and tools that allow a better also be discussed. characterisation of HTS hits by experimental and calculated data. Tools were Michael Dillon, Director, Medicinal Chemistry, also developed that help display those characteristics in a convenient fashion. Roche Palo Alto This session will discuss: • Improvements that have been implemented in high throughput screening 17:45 Chair’s summary and close of day one • What data is being used for the characterisation of hits • How the data is provided to help prioritisation of hit and lead series Michael Arlt, Department Manager, Global Medicinal Chemistry Lead Finding, Merck KGaA DAY TWO: 19th July 2005 12:00 Optimising DMPK properties in hit-to-lead – an AstraZeneca 08:30 Coffee and registration perspective DMPK properties are being assessed much earlier in drug discovery now to 09:00 Chair’s welcome avoid complications in lead optimisation. In this session, AstraZeneca will Iain McFadyen, Senior Research Scientist II, Chemistry and Screening Sciences, review their approach and show how early DMPK analysis has influenced Wyeth projects downstream. • Optimising compounds using experimental and computational tools 09:15 Optimising ligand-based approaches to virtual screening • Using DMPK data to drive hit-to-lead projects Given an initial hit, similarity searching provides a simple way of prioritising • Safety considerations: reactive metabolites etc compounds in a corporate or public database for biological testing, and thus of Richard Weaver, Team Leader, DMPK Research, Physical and Metabolic Sciences, identifying potential new leads. This session will describe recent work that AstraZeneca provides effective tools for fingerprint-based virtual screening. • Conventional approaches to similarity-based virtual screening 12:45 Enhancing profiling strategies: Compound prioritisation and • Use of nearest neighbour information to increase search effectiveness optimisation • Combination of similarity searches when several hits are available Inpharmatica has developed an interactive and visually engaging interface, Peter Willett, Head, Department of Information Studies, Admensa InteractiveTM, which allows scientists to select compounds with the University of Sheffield best overall balance of properties and potential for success. The interface also includes a predictive ADME modelling suite, the results of which can be 10:00 Identifying and assessing potential leads through structure- incorporated with any in vitro and in vivo measurements (such as potency and based virtual screening selectivity) in a unique prioritisation suite. This presentation will give a brief Structure-based virtual screening has become an important tool in the hit-to- overview of Admensa InteractiveTM and will share a number of case studies lead process. This session will explore how this technique can be applied in demonstrating its applicability in the hit-to-lead stages of drug discovery. order to aid lead generation and assessment. Joelle Gola, Computational Chemist, ADME modelling, • Generating plausible hypotheses for molecular recognition (pose prediction) Inpharmatica • Rank-ordering potential lead series (affinity prediction) • Generating and assessing potential leads (fragment screening) 13:15 Networking lunch Romano Kroemer, Head of Drug Design, Sanofi-Aventis 14:15 Generating high quality candidates for effective hit-to-lead This presentation will explore how Novartis uses HTS to effectively support hit- 10:45 Coffee +44 (0)20 7368 9300 +44 (0)20 7368 9301 www.iqpc-pharma.com/2484a UK Freephone: 0800 652 2363 [email protected] 11:15 Lead-hopping via structure-based drug design 16:15 2nd generation kinase inhibitors In order to increase the chances of success against a given target, it is a great • Small
Recommended publications
  • On the Organization of a Drug Discovery Platform
    DOI: 10.5772/intechopen.73170 ProvisionalChapter chapter 2 On the Organization of a Drug Discovery Platform Jean A. Boutin,A. Boutin, Olivier NosjeanOlivier Nosjean and Gilles FerryGilles Ferry Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.73170 Abstract Some of the most exciting parts of work in the pharmaceutical industry are the steps lead- ing up to drug discovery. This process can be oversimplified by describing it as a screen- ing campaign involving the systematic testing of many compounds in a test relevant to a given pathology. This naïve description takes place without taking into consideration the numerous key steps that led up to the screening or the steps that might follow. The present chapter describes this whole process as it was conducted in our company dur- ing our early drug discovery activities. First, the purpose of the procedures is described and rationalized. Next follows a series of mostly published examples from our own work illustrating the various steps of the process from cloning to biophysics, including expression systems and membrane-bound protein purifications. We believe that what is described here presents an example of how pharmaceutical industry research can orga- nize its platform(s) when the goal is to find and qualify a new preclinical drug candidate using cutting-edge technologies and a lot of hard work. Keywords: drug discovery, validation, cloning & expression, biophysics, structural biology, organization 1. Introduction Drug discovery involves a suite of processes as part of a program aimed at finding drug thera- pies for diseases. These programs encompass many different scientific steps from validation of the target (or attempts to do so) and characterization of the hits until the selection of can- didates for medicinal chemistry programs.
    [Show full text]
  • Predicting Strategies for Lead Optimization Via Learning to Rank
    IPSJ Transactions on Bioinformatics Vol.11 41–47 (Dec. 2018) [DOI: 10.2197/ipsjtbio.11.41] Original Paper Predicting Strategies for Lead Optimization via Learning to Rank Nobuaki Yasuo1,2,a) Keisuke Watanabe1 Hideto Hara3 Kentaro Rikimaru3 Masakazu Sekijima1,4,b) Received: August 21, 2018, Accepted: September 18, 2018 Abstract: Lead optimization is an essential step in drug discovery in which the chemical structures of compounds are modified to improve characteristics such as binding affinity, target selectivity, physicochemical properties, and tox- icity. We present a concept for a computational compound optimization system that outputs optimized compounds from hit compounds by using previous lead optimization data from a pharmaceutical company. In this study, to predict the drug-likeness of compounds in the evaluation function of this system, we evaluated and compared the ability to correctly predict lead optimization strategies through learning to rank methods. Keywords: lead optimization, learning to rank, computer-aided drug design, machine learning computer-aided drug discovery (CADD), which has been utilized 1. Introduction since the 1960s, are also leading current drug discovery. The During drug discovery, enormous attempts are being made to methods of CADD can be combined with various biological data identify better drug candidates. Since the cost of drug discovery including genomic sequence, protein tertiary structure, and chem- has been drastically increased, recently the process of drug dis- ical structure, and can be utilized in various steps in drug discov- covery typically takes 12–14 years [1] and costs approximately ery: target identification, compound screening, and ADME (ab- 2.6 billion USD [2]. The process of drug discovery is sometimes sorption, distribution, metabolism, excretion, toxicity) properties likened to looking for a needle in a haystack; it is the process prediction [9], [10], [11].
    [Show full text]
  • Medicinal Chemistry for Drug Discovery | Charles River
    Summary Medicinal chemistry is an integral part of bringing a drug through development. Our medicinal chemistry approach enables clients to benefit from efficient navigation of the early drug discovery process through to delivery of preclinical candidates. DISCOVERY Click to learn more Medicinal Chemistry for Drug Discovery Medicinal Chemistry A Proven Track Record in Drug Discovery Services: Our medicinal chemistry team has experience in progressing small molecule drug discovery programs across a broad range • Target identification of therapeutic areas and gene families. Our scientists are skilled in the design and synthesis of novel pharmacologically active - Capture Compound® mass compounds and understand the challenges facing modern drug discovery. Together, they are cited as inventors on over spectrometry (CCMS) 350 patents and have identified 80 preclinical candidates for client organizations across a variety of therapeutic areas. As • Hit-finding strategies project leaders, our chemists are fundamental in driving the program strategy and have consistently empowered our clients’ - Optimizing high-throughput success. A high proportion of candidates regularly progress to the clinic, and our first co-invented drug, Belinostat, received screening (HTS) hits marketing approval in 2015. As an organization, Charles River has worked on 85% of the therapies approved in 2018. • Hit-to-lead We have a deep understanding of the factors that drive medicinal chemistry design: structure-activity relationship (SAR), • Lead optimization biology, physical chemistry, drug metabolism and pharmacokinetics (DMPK), pharmacokinetic/pharmacodynamic (PK/PD) • Patent strategy modelling, and in vivo efficacy. Charles River scientists are skilled in structure-based and ligand-based design approaches • Preparation for IND filing utilizing our in-house computer-aided drug design (CADD) expertise.
    [Show full text]
  • DMPK) Studies Are Critical to Efficient Drug Discovery Programs and Successful Delivery of Candidate Molecules
    Summary Discovery drug metabolism and pharmacokinetics (DMPK) studies are critical to efficient drug discovery programs and successful delivery of candidate molecules. DISCOVERY Drug Metabolism and Pharmacokinetics (DMPK) Click to learn more Supporting Discovery Research DMPK Services The identification and inclusion of appropriate DMPK studies is key to the success of discovery research by helping to de-risk • In vitro ADME candidate molecules and improve project productivity through more targeted chemical synthesis and progression of the right compounds. Charles River’s flexible and collaborativeDMPK team offers a variety of partnerships and pricing structures to suit • Physicochemical properties client needs. In addition to fee-for-service assays and expertise, we can embed our DMPK scientists within existing integrated • Metabolic stability chemistry programs as core team members of multidisciplinary project teams. We offer a wealth of experience in a range of • Drug-drug interactions therapeutic areas and biological targets and can help support strategy and implementation of appropriate screening cascades. • Distribution • Safety • High-throughput and automation Chemistry • Pharmacokinetics (PK) support • Bioanalysis and Biology pharmacokinetic support DMPK Questions for our chemists? Visit https://www.criver.com/ consult-pi-ds-questions-for-our- chemists EVERY STEP OF THE WAY www.criver.com In Vitro ADME As compound potency improves during hit-to-lead and lead optimization, in vitro ADME assays provide necessary data to establish insight into the key physiochemical properties and structural motifs that will provide the targeted candidate profile. Our in vitro ADME scientists have established a suite of assays that routinely support drug discovery programs, continue to work on the development and validation of new assays, and regularly monitor assay performance.
    [Show full text]
  • Early Hit-To-Lead ADME Screening Bundle Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
    Fact Sheet Early Hit-to-Lead ADME Screening Bundle Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery In vitro ADME screening during the lead optimization stage of drug discovery positively impacts drug candidate selection with an enhanced probability of success in clinical trials. Since most new drug candidates fail during preclinical and clinical development, and the late stage of the drug development cycle can be a lengthy and costly process, any means of identifying drug candidates with optimized ADME and pharmacokinetics properties in the discovery stage will have a significant impact on the drug discovery process overall. Focused on Solutions to Address DMPK Issues and to Enable the Success of Our Clients Our scientists routinely conduct industry standard in vitro metabolism and DDI-based assays, including highly automated ADME in vitro screens. We can help drive your discovery phase structure activity relationship (SAR) by optimizing for ADME properties, in parallel to your receptor binding potency and selectivity, for more rapid identification of high quality drug candidates. Metabolic stability, risk assessment for inhibiting key Cytochrome P450 enzymes, and cell permeability are three main early hit-to-lead ADME screening assays that all new chemical entities (NCEs) are tested for in the industry in effort to optimize key ADME properties. In Vitro ADME Screening Services: Early Hit-to-Lead ADME Screening Bundle Intrinsic Clearance Assay in Liver Microsomes • Liver microsomes; species selectable • Incubation
    [Show full text]
  • A New Ligand-Based Approach to Virtual Screening and Profiling of Large Chemical Libraries
    A new ligand-based approach to virtual screening and profiling of large chemical libraries Elisabet Gregori Puigjané Memòria presentada per optar al grau de Doctor en Biologia per la Universitat Pompeu Fabra. Aquesta Tesi Doctoral ha estat realitzada sota la direcció del Dr. Jordi Mestres al Departament de Ciències Experimentals i de la Salut de la Universitat Pompeu Fabra Jordi Mestres Elisabet Gregori Puigjané Barcelona, Maig 2008 The research in this thesis has been carried out at the Chemogenomics Laboratory (CGL) within the Unitat de Recerca en Informàtica Biomèdica (GRIB) at the Parc de Recerca Biomèdica de Barcelona (PRBB). The research carried out in this thesis has been supported by Chemotargets S. L. Table of contents Acknowledgements ........................................................................................... 3 Abstract .............................................................................................................. 5 Objectives ........................................................................................................... 7 List of publications ............................................................................................ 9 Part I – INTRODUCTION .................................................................................. 11 Chapter I.1. Drug discovery ..................................................................... 13 I.1.1. Obtaining a drug candidate ....................................................... 14 I.1.1.1. Hit identification ..........................................................
    [Show full text]
  • An Emerging Strategy for Rapid Target and Drug Discovery
    R E V I E W S CHEMOGENOMICS: AN EMERGING STRATEGY FOR RAPID TARGET AND DRUG DISCOVERY Markus Bredel*‡ and Edgar Jacoby§ Chemogenomics is an emerging discipline that combines the latest tools of genomics and chemistry and applies them to target and drug discovery. Its strength lies in eliminating the bottleneck that currently occurs in target identification by measuring the broad, conditional effects of chemical libraries on whole biological systems or by screening large chemical libraries quickly and efficiently against selected targets. The hope is that chemogenomics will concurrently identify and validate therapeutic targets and detect drug candidates to rapidly and effectively generate new treatments for many human diseases. Over the past five decades, pharmacological compounds however, that owing to the emergence of various sub- TRANSCRIPTIONAL PROFILING The study of the transcriptome have been identified that collectively target the products specialties of chemogenomics (discussed in the next — the complete set of RNA of ~400–500 genes in the human body; however, only section) and the involvement of several disciplines, it is transcripts that are produced by ~120 of these genes have reached the market as the tar- currently almost impossible to give a simple and com- the genome at any one time — gets of drugs1,2. The Human Genome Project3,4 has mon definition for this research discipline (BOX 1). using high-throughput methods, such as microarray made available many potential new targets for drug In chemogenomics-based drug discovery, large col- analysis. intervention: several thousand of the approximately lections of chemical products are screened for the paral- 30,000–40,000 estimated human genes4 could be associ- lel identification of biological targets and biologically ated with disease and, similarly, several thousand active compounds.
    [Show full text]
  • Hit-To-Lead (H2L) and Lead Optimization in Medicinal Chemistry
    Hit-to-lead (H2L) and Lead Optimization in Medicinal Chemistry 1 This document provides an outline of a presentation and is incomplete without the accompanying oral commentary and discussion. Drug Discovery: Lead Optimization 2 Lecture Overview • Ligand-protein interactions. • Physico-chemical properties and drug design: attributes of a lead molecule. • Introduction to medicinal chemistry and lead optimization. • Best practices in medicinal chemistry. • Case-studies (Alzheimer’s disease): – Fragment-based approaches in discovery of beta- secretase inhibitors – Identification of a PDE9 clinical candidate 3 Lecture Overview • Ligand-protein interactions. • Physico-chemical properties and drug design: attributes of a lead molecule. • Introduction to medicinal chemistry and lead optimization. • Best practices in medicinal chemistry. • Case-studies (Alzheimer’s disease): – Fragment-based approaches in discovery of beta- secretase inhibitors – Identification of a PDE9 clinical candidate 4 Ligand-protein binding event SolutionSolução ComplexComplexo Gbind + Something to remember: 1.36 kcal/mol ~ 10-fold gain in affinity 2.72 kcal/mol ~ 100-fold 4.08 kcal/mol ~ 1000-fold 5 Some Factors Affecting Gbind Favor Binding Oppose Binding Entropy and enthalpy gain due to the “hydrophobic effect” – taking ligand out of Ligand desolvation enthalpy – loss of water eliminates the penalty associated with the interactions with the solvent. solvent cavity creation. Entropy and enthalpy gain due to the Binding pocket desolvation enthalpy – loss of “hydrophobic effect” for ordered waters bound interactions with the solvent. to protein moving to bulk solvent. Residual vibrational entropy in protein-ligand Translational and rotational entropy loss for complex. ligand and protein upon binding (loss of 3 translational and 3 rotational degrees of freedom).
    [Show full text]
  • Hit Discovery and Hit-To-Lead Approaches Reviews
    Drug Discovery Today Volume 11, Numbers 15/16 August 2006 REVIEWS POST SCREEN Hit discovery and hit-to-lead approaches Reviews Gyo¨ rgy M. Keseru˝ 1 and Gergely M. Makara2 1 CADD&HTS Unit, Gedeon Richter Ltd, 19-21 Gyo¨mro˝iu´t, Budapest, H-1103, Hungary 2 Merck Research Laboratories, Merck & Co, RY80Y-325, 126 E. Lincoln Ave, Rahway, New Jersey, 07065, USA Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques and computer-aided de novo design, many of which have been extensively reviewed. Development of quality leads using hit confirmation and hit-to-lead approaches present their own challenges, depending on the hit discovery method used to identify the initial hits. In this paper, we summarize common industry practices adopted to tackle hit-to-lead challenges and review how the advantages and drawbacks of different hit discovery techniques could affect the various issues hit-to-lead groups face. It has been shown that marketed drugs are very frequently highly All hit discovery approaches have – often orthogonal – short- similar to the leads from which they were derived [1]. Thus, both comings prompting the frequent use of multiple techniques for hit the quality and the quantity of lead classes available to medicinal confirmation (Table 1). Challenges facing traditional HTS tech- chemists are primary drivers for discovering best-in-class medi- nologies include high false-positive rates, the need for reporter cines. This makes lead generation a crucial step in the drug dis- assays and the limitation in throughput imposed by testing com- covery process.
    [Show full text]
  • Drug Development
    DRUG DEVELOPMENT www.acuteleuk.org Drug Development Process Only about 2% of substances evaluated in early research make it to the market as new medicines Number of drugs in the R&D pipeline Number of drugs in the R&D pipeline worldwide 2019 vs. 2020, by development phase Source: https://www.statista.com/ A minimum of a 10-year plan It takes over 10 years and on average costs between €400 million and €1.5 billion before a new medicine can be made available to patients and reimbursement starts Drug development means … What is the rationale to initiate drug development ? • Scientific and Intellectual Property – How does the drug work? • Molecule structure and properties • Mechanism of action • Biological activity (bioassays, drug/target interaction, affinity, specificity,…) – What data support the approach? • Literature validation • In-house preclinical/clinical data – Who owns the intellectual property? What is the rationale to initiate drug development ? • Disease overview and unmet medical need – What is known about disease pathogenesis (translational medicine)? – Where in the disease process should drug enter? Greatest unmet need? – Is this disease part of a disease family? If so which fits best with drug and regulatory history? Is there an orphan approach? – Is this disease field crowded? – Has the indication been clinically studied before (in drug studies)? – What is the event rate for target medical problems? (Make the statisticians happy) – Are there “approvable” endpoints for the unmet needs? – If not, what endpoints seem reasonable:
    [Show full text]
  • Computational Methods Used in Hit-To-Lead and Lead Optimization Stages of Structure-Based Drug Discovery
    Computational methods used in Hit-to-Lead and Lead Optimization stages of structure-based drug discovery Alexander Heifetz1,2*, Michelle Southey1, Inaki Morao1, Andrea Townsend-Nicholson2 and Mike J. Bodkin1 1Evotec Ltd, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK 2Institute of Structural & Molecular Biology, Research Department of Structural & Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, United Kingdom *Corresponding author Keywords: Structure based drug design; molecular dynamics; simulation; Hit-to-lead, Lead optimization; G-protein coupled receptor; docking; 1 Summary GPCR modeling approaches are widely used in the hit-to-lead (H2L) and lead optimization (LO) stages of drug discovery. The aims of these modeling approaches are to predict the 3D structures of the receptor-ligand complexes, to explore the key interactions between receptor and ligand and to utilize these insights in the design of new molecules with improved binding, selectivity or other pharmacological properties. In this book chapter, we present a brief survey of key computational approaches integrated with hierarchical GPCR modeling protocol (HGMP) used in hit-to-lead (H2L) and in lead optimization (LO) stages of structure based drug discovery (SBDD). We outline the differences in modeling strategies used in H2L and LO of SBDD. We illustrate how these tools have been applied in three drug discovery projects. 1. Introduction 1.1 GPCRs are cell surface receptors that contain seven transmembrane helices and constitute the largest superfamily of membrane proteins, regulating almost every aspect of cellular activity [1]. GPCRs have enormous physiological and biomedical importance, being the primary site of action of 40% of all prescribed drugs today [2].
    [Show full text]
  • Oversight Committee Board Packet
    Oversight Committee Meeting February 21, 2018 Summary Overview of the February 21, 2018, Oversight Committee Meeting This summary provides an overview of major agenda items and background on key issues for Committee consideration at the February 21, 2018, Oversight Committee meeting. CEO Report Wayne Roberts will present the CEO’s report and address issues including new personnel, available grant funds, and other topics. Mr. Roberts will also present his annual report required by Tex. Health & Safety Code § 102.260(c). Grantee Presentation – Asuragen, Inc. Dr. Gary Latham will report on Asuargen’s activities and achievements. Asuragen received a $6.8 million Commercialization/Product Development grant in 2012. Chief Compliance Officer Report Vince Burgess will report on the status of required grantee reports, financial status report reviews, desk reviews and site visits, annual compliance attestation, single audit tracking, and training. Chief Scientific Officer Report and Grant Award Recommendations Dr. James Willson will provide an update on the Academic Research Program and present the Program Integration Committee’s (PIC) award recommendations for Academic Research grant awards. CPRIT does not publicly disclose information related to the Academic Research grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. Chief Prevention and Communications Officer Report and Grant Award Recommendations Dr. Becky Garcia will report to the Oversight Committee on the Prevention Program activities and present the PIC’s award recommendations for Prevention grant awards. She will also present the agency’s communications update, including a review of CPRIT’s 2017 Innovations Conference.
    [Show full text]